GSK shares: should I buy now?

GSK (LON:GSK) shares have settled after yesterday’s big news. Paul Summers reflects on the arguments for and against buying now.

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

A GlaxoSmithKline scientist uses a microscope

Image: GlaxoSmithKline

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

I’ve been willing to give pharma giant GlaxoSmithKline (LSE: GSK) the benefit of the doubt over the years. While GSK shares have remained stuck within the trading range of 1,000p–2,000p for over two decades, the dividend stream has remained rewarding for those owning the stock.

Does confirmation of a forthcoming cut to the payout change things? Here’s my take.

Wait – the dividend’s being cut?!

That’s the plan. Let’s briefly recap yesterday’s news. It was announced Glaxo would list its consumer healthcare business as a separate company in the middle of 2022. By doing this, the FTSE 100 member aims to generate cash to use for developing drugs at its pharmaceutical business (New GSK). The latter has struggled in recent years due to a wobbly pipeline. Clearly, the global pandemic hasn’t helped either. Glaxo said it was now aiming to grow sales here by more than 5% a year to 2026. 

In line with this plan, Glaxo announced yesterday that its big-but-stagnant annual payout would be cut. In 2022, the aggregate dividend from GSK and the now separate New Consumer Healthcare business will likely be 55p. That’s a little over 30% lower than the amount investors currently receive (80p). From 2023, New GSK will pay 45p per share to holders. 

While this cut is far from insignificant, it’s less than analysts had feared. This may explain why the GSK share price reacted favourably to yesterday’s news, at least initially. Unfortunately, this buying pressure gradually dissipated as the day went on as investors digested the news.

So, would I buy GSK shares now?

On the one hand, I do see some upside. Historically, many spin-offs tend to have done well once they’ve been released from the shackles of their parent companies. Considering the strong brands it shares with Pfizer (Sensodyne toothpaste, Advil painkillers), I’m can instantly think of worse firms to be invested in than New Consumer Healthcare.

Owning shares of both businesses in such defensive sectors might also be prudent if (and that’s a big ‘if’) markets become increasingly choppy as inflation fears grow. Moreover, GSK shares look good value relative to peers at 14 times forecast earnings. And while a dividend cut is never good news for income investors, the payouts should still be attractive enough. 

On the flip-side, I do understand why some existing holders may be mulling over whether to sell. Yes, the pandemic has proved disruptive for most businesses. Nevertheless, the GSK share price hasn’t fared well under CEO Emma Walmsley’s leadership.

Sure, earnings targets provide clarity and sound great on paper, but I’m sceptical over whether the new strategy can really be achieved under the current management team. Drug development can also be a painfully slow process, regardless of who’s in charge and how much money is thrown at it.

Bottom line

Time will tell whether those owning GSK shares are truly willing to embrace the new strategy. If I already held the shares, I’d probably keep holding for the income they generate and hope dividends would rise in time.

If I favoured capital growth over income and didn’t already own the stock however, I’d certainly take the time to look at other opportunities. Today’s rather muted opening suggests I’m not the only one to think that greater gains can be achieved elsewhere. 

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Paul Summers has no position in GlaxoSmithKline. The Motley Fool UK has recommended GlaxoSmithKline. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Dividend Shares

£3k in savings? Investors could consider putting it here for juicy second income

Jon Smith talks through how investors could buy dividend stocks with yield potential in excess of 6.5% for second income

Read more »

Shot of a young Black woman doing some paperwork in a modern office
Investing Articles

Why the boohoo share price soared by almost 14% in November

Is troubled online fashion retailer boohoo beginning a turnaround that may cause the share price to rocket through 2025 and…

Read more »

Young Asian woman holding a cup of takeaway coffee and folders containing paperwork, on her way into the office
Investing Articles

Here’s how saving £5.40 a day could net me £1,971 yearly passive income for life

The price of a cup of coffee seems to have broken the £5 mark. Is it time to put that…

Read more »

Investing Articles

2 top FTSE 100 stocks surging to record highs (hint — not Rolls-Royce)!

Ben McPoland takes a closer look at a pair of high-performing FTSE 100 stocks that continue to enrich long-term shareholders.

Read more »

Investing Articles

A cheap FTSE 100 share to consider buying for the next 10 years!

This FTSE 100 share has pride of place in my portfolio. Here's why I think it could be a top…

Read more »

Snowing on Jubilee Gardens in London at dusk
Investing Articles

Down 44% in 2 months! Is this FTSE 250 green energy pioneer priced too cheaply?

After a sharp tumble in recent months, this FTSE 250 company with a growing order book is almost 90% below…

Read more »

Investing Articles

Investing a £20k Stocks and Shares ISA in this high-yielder might give me a £2,000 annual income

Harvey Jones is now wondering whether to pour his entire Stocks and Shares ISA allowance into a single FTSE 100…

Read more »

Investing Articles

Saving £20k in an ISA? Here’s how I’m aiming to turn that into a stunning £2,035 monthly passive income

Harvey Jones is keen to build a high and rising passive income by investing in a balanced spread of top…

Read more »